Drugs in Development
All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Tadekinig alfa
Therapeutic Area: Immunology Product Name: r-hIL-18BP
Highest Development Status: Phase III Product Type: Large molecule
Partner/Sponsor/Collaborator: AB2 Bio
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration October 29, 2020
Details:
Tadekinig alfa is a novel IL-18 binding protein in pivotal Phase 3 testing for orphan disease IL-18 driven monogenic Hemophagocytic Lymphohistiocytosis (HLH). WuXi Biologics to undertake commercial scale manufacturing to support U.S. market launch.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Telitacicept
Therapeutic Area: Immunology Product Name: Undisclosed
Highest Development Status: Phase III Product Type: Large molecule
Partner/Sponsor/Collaborator: Lilly Asia Ventures
Deal Size: $100.0 million Upfront Cash: Undisclosed
Deal Type: Financing April 02, 2020
Details:
Funds will support clinical trials and commercialization for its autoimmune, oncology and ophthalmology pipeline.
Market Place
Active Pharmaceutical Ingredients
Finished Drug Formulations
Price
Excipients
Services
Marketplace
